Four IP takeaways from Novartis’ $9.7 billion acquisition of The Medicines Company
Over the weekend, Novartis struck one of the largest deals in the biopharma sectors this year, agreeing to pay $9.7 billion for cardiovascular specialist The Medicines Company
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10